Persistent APRIL and BAFF activation promotes survival advantages in MM and DLBCL, facilitating disease progression and treatment resistance (Kuo et al., 2008; Moreaux et al., 2004). The gene discussed is TNFSF13; the disease is diffuse large B-cell lymphoma.